Non-cirrhotic non-alcoholic steatohepatitis with fibrosis research hub

A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele.

This study is testing a new medicine, AZD2693, for people with a specific type of liver disease called NASH. It's looking at how well the medicine works and if it's safe, especially in those with a particular gene marker and early liver scarring.